重症肺炎患者免疫治疗前后免疫功能的变化  

Study of the immune function before and after immunotherapy in patients with severe pneumonia

作　　者：占林兵[1] 谢波[1] 华锋[1] 富明民[1] 

机构地区：[1]浙江省湖州市中心医院重症医学科,313000

出　　处：《实用医学杂志》2015年第13期2145-2147,共3页The Journal of Practical Medicine

基　　金：浙江省卫生厅项目(编号:2011KYA153)

摘　　要：目的:研究免疫治疗对重症肺炎患者CD14+单核细胞人白细胞抗原-DR(m HLA-DR)表达率、血清免疫球蛋白Ig G、Ig A和Ig M指标的影响,探讨重症肺炎免疫治疗的价值。方法:选取本院2012年1月至2014年4月收治的重症肺炎患者120例,随机分为对照组60例和治疗组60例,对照组患者给予常规治疗,治疗组在常规治疗的基础上给予胸腺肽α1治疗,疗程为7 d。比较两组治疗前后m HLA-DR表达以及Ig G、Ig A和Ig M含量变化。结果 :治疗组胸腺肽α1治疗后m HLA-DR表达率升高显著,同时血清Ig G、Ig A和Ig M含量均出现明显升高,治疗前后差异均具有统计学意义(P<0.05),而对照组治疗前后上述指标的差异无统计学意义(P>0.05)。结论:重症肺炎患者采用胸腺肽α1免疫治疗可以预防免疫抑制,明显提高患者机体免疫功能。Objective To study the effect of immunotherapy on expression of CD14, mHLA-DR and the serum levels of immunoglobulin （IgG, IgA and IgM） in patients with severe pneumonia, so as to discuss the feasibility of immunotherapy for severe pneumonia. Methods From January 2012 to April 2014, 120 cases of patients with severe pneumonia treated in the intensive care unit （ICU） and pneumonia department were collected. Patients were randomly divided into control group （60 cases） and treatment group （60 cases）. The control group was administrated with conventional therapy, and the treatment group was given thymosin otl for immune treatment for 7 days. The mHLA-DR expression and the level of IgG, IgA and IgM of the two groups before and after the treatment were compared. Results After thymosin oL1 treatment, mHLA-DR expression rate was elevated, and the serum levels of IgG, IgA and IgM were elevated in the treatment group, and the difference was statistically significant （P 〈 0.05）. While there was no statistically significant difference between the above indicators before and after treatment （P 〉 0.05）. Conclusion After immune treatment with the use of thymosin ctl, immunologic suppression can be prevented, and cellar immune function of severe pneumonia patients can be improved.

关 键 词：重症肺炎 免疫治疗 免疫球蛋白 单核细胞人白细胞抗原-DR 

分 类 号：R563.1[医药卫生—呼吸系统]